Stocks in play: Sernova Corp.
Announces developments in its Phase I/II clinical trial investigating a novel treatment for Type 1 Diabetes (T1D). To date a total of seven patients across Cohorts 1 and 2 have achieved insulin independence following transplants of human donor islets via Sernova’s proprietary Cell Pouch System™ and a marginal portal vein top up. Additionally, the study, which is being conducted at the University of Chicago, completed full enrollment of the second cohort of patients with the last patient being enrolled June 24. Sernova Corp. shares T.SVA are trading up $0.02 at $0.39.
Read:
Tech Giants Drive AI Advancements as US Considers New Investment Rules for China
Private Sector Pushes Forward: Big Tech and AI Startups Thrive Amid Geopolitical Strife
Revolutionizing Enterprise Operations: Key Advancements in AI Infrastructure and Supplies
AI Adoption: Transforming the Future Economy with Boosted GDP and Productivity
Oncology Market Rising Towards $564.5B Amid Cancer Spike and Biotech Innovations